Structural modulation of the gut microbiota and the relationship with body weight: compared evaluation of liraglutide and saxagliptin treatment
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
The mechanisms underlying the weight-loss effect of GLP-1 receptor agonists need further elucidation. The present study was performed to explore the effects of liraglutide and saxagliptin on the composition of the gut microbiota. Mice were randomly treated with saxagliptin or liraglutide for eight weeks. Their metabolic profiles were assessed, and 454 pyrosequencing of 16s rRNA of faeces was performed. Liraglutide induced a smaller body weight gain in mice. The pyrosequencing showed that liraglutide, but not saxagliptin, substantially changed the overall structure of the gut microbiota as well as the relative abundance of weight-relevant phylotypes. Subsequent ridge regression analyses indicated that, in addition to food intake (β = −0.182, p = 0.043 in phylotypes inversely correlated with body weight) and blood glucose level (β = −0.240, p = 0.039 in phylotypes positively correlated with body weight), the administration of liraglutide was another independent factor associated with the abundance of weight-relevant phylotypes (β = 0.389, p = 6.24e-5 in inversely correlated ones; β = −0.508, p = 2.25e-5 in positively correlated ones). These results evidenced that GLP-1 receptor agonist liraglutide could modulate the composition of the gut microbiota, leading to a more lean-related profile that was consistent with its weight-losing effect.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The authors [42] observed that liraglutide (but not saxagliptin) causes a lower expression of obesity-related philotypes (including Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia and Parabacteroides), while on the contrary it promotes the growth of the philotypes Blautia and Coprococcus, which are related to a lower body mass index.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [42]
In the citing paper
“The authors [42] observed that liraglutide (but not saxagliptin) causes a lower expression of obesity-related philotypes (including Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia and Parabacteroides), while on the contrary it promotes the growth of the philotypes Blautia and Coprococcus, which are related to a lower body mass index.”
From GLP-1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art (2022) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
UPARSE: highly accurate OTU sequences from microbial amplicon reads
Edgar, R. C. (2013) · Nature Methods · doi:10.1038/nmeth.2604 · Cited by 16,707
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
The Elements of Statistical Learning: Data Mining, Inference, and Prediction
John Lu, Z. Q. (2010) · Journal of the Royal Statistical Society Series A: Statistics in Society · doi:10.1111/j.1467-985x.2010.00646_6.x · Cited by 12,390
Statistical significance for genomewide studies
Storey, J. D., & Tibshirani, R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1530509100 · Cited by 9,692
Human gut microbes associated with obesity
Ley, R. E., Turnbaugh, P. J., Klein, S., & Gordon, J. I. (2006) · Nature · doi:10.1038/4441022a · Cited by 8,785
UniFrac: a New Phylogenetic Method for Comparing Microbial Communities
Lozupone, C., & Knight, R. (2005) · Applied and Environmental Microbiology · doi:10.1128/aem.71.12.8228-8235.2005 · Cited by 8,227
Enterotypes of the human gut microbiome
MetaHIT Consortium (additional members), Arumugam, M., Raes, J., Pelletier, E., Le Paslier, D., Yamada, T., Mende, D. R., Fernandes, G. R., Tap, J., Bruls, T., et al. (2011) · Nature · doi:10.1038/nature09944 · Cited by 7,548
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176
Cited by
Items 101–166 of 166
Comparison study of gut microbiota in case of Parkinson’s disease and other neurological disorders
Петров, В. А., Alifirova, V. M., Saltykova, I. V., Zhukova, I. A., Жукова, Н. Г., Dorofeeva, Y. B., Tyakht, A., Altukhov, I. A., Kostryukova, E., Titova, M. A., et al. (2016) · Bulletin of Siberian Medicine · doi:10.20538/1682-0363-2016-5-113-125 · Cited by 21
Recent update on biological activities and pharmacological actions of liraglutide
Tiwari, J., Gupta, G., Dahiya, R., Pabreja, K., Sharma, R. K., Mishra, A., & Dua, K. (2017) · EXCLI journal · doi:10.17179/excli2017-323 · Cited by 17
“Wang et al., 2016a Through modification of AMPK/mTOR signaling, LG weakens osteoblastic differentiation of MC3T3 E1 cells.”
BackgroundFecal microbiota transplantation in a rodent model of short bowel syndrome: A therapeutic approach?
Fourati, S., Dumay, A., Roy, M., Willemetz, A., Ribeiro‐Parenti, L., Mauras, A., Mayeur, C., Thomas, M., Kapel, N., Joly, F., et al. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1023441 · Cited by 17
“The inocula were enriched in Firmicutes over Bacteroidota which is also a known characteristic of obese subjects’microbiota (Wang et al., 2016; Gomes et al., 2018).”
BackgroundGarcía, S. I., Ordoñez, S., López-Molina, V. M., Lacruz-Pleguezuelos, B., Pau, E. C. D. S., & Marcos-Zambrano, L. J. (2023) · Gut Microbes · doi:10.1080/19490976.2023.2241207 · Cited by 16
Tang, Y., Yan, M., Fang, Z., Jin, S., & Xu, T. (2024) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2023-003837 · Cited by 19
Schots, P. C., Jansen, K. M., Mrázek, J., Pedersen, A. M., Olsen, R. L., & Larsen, T. S. (2020) · Nutrition Research · doi:10.1016/j.nutres.2020.09.002 · Cited by 16
Zhang, L., Luo, J., Li, X., Guo, S., & Shi, D. (2020) · Marine Drugs · doi:10.3390/md18090469 · Cited by 19
“However, saxagliptin, a DPP-4i inhibitor, had the opposite effect, which increased the Firmicutes/Bacteroidetes ratio [30].”
BackgroundDysbiosis versus diabesity: Pathological signaling and promising therapeutic strategies
Sharma, A. K., Sharma, A., Lal, S., Kumar, A., Yadav, N. K., Tabassum, F., Akhtar, M. S., Imam, M. T., Almalki, Z. S., & Mukherjee, M. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103558 · Cited by 15
The Genetic Blueprint of Obesity: From Pathogenesis to Novel Therapies
Tonin, G., Eržen, S., Mlinarič, Z., Jurišić‐Eržen, D., Horvat, S., Kunej, T., & Klen, J. (2025) · Obesity Reviews · doi:10.1111/obr.13978 · Cited by 17
Otmani, S. E., Chebli, Y., Taminiau, B., Chentouf, M., Hornick, J., & Cabaraux, J.-F. (2021) · Biology · doi:10.3390/biology10121237 · Cited by 17
“Marvinbryantia tended to be higher with 30% CC that could be one of the responsible factors of the lean meat of animals receiving CC because this genus is related negatively to weight and provide acetic acid from cellulose and methylcellulose degradation [66].”
BackgroundGanamurali, N., & Sabarathinam, S. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01834-y · Cited by 16
Lu, C., Xu, C., & Yang, J. (2024) · Medicina · doi:10.3390/medicina61010017 · Cited by 14
Xie, A., Song, J., Lü, S., Liu, Y., Tang, L., & Wen, S. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.737622 · Cited by 13
“DNA isolation and 16S rRNA gene sequencing were provided by Novogene (Beijing, China), as described previously (Wang et al., 2016; Zhang et al., 2018), to ascertain the composition of the bacteria in the feces of rats in different groups.”
MethodRibeiro, G., Schellekens, H., Cuesta‐Marti, C., Maneschy, I. R., Ismael, S., Cuevas‐Sierra, A., Martínez, J. A., Silvestre, M. P., Marques, C., Moreira-Rosário, A., et al. (2025) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00227.2024 · Cited by 14
Lew, K. N., Starkweather, A. R., Cong, X. S., & Judge, M. P. (2019) · Biological Research For Nursing · doi:10.1177/1099800419849109 · Cited by 13
Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
Zeng, D.-K., Xiao, Q., Li, F., Tang, Y.-Z., Jia, C.-L., & Tang, X.-W. (2019) · Bioscience Reports · doi:10.1042/bsr20190980 · Cited by 14
Consumption of salt leads to ameliorate symptoms of metabolic disorder and change of gut microbiota
Do, M. H., Lee, H., Oh, M., Jhun, H., Ha, S. K., & Park, H. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02209-0 · Cited by 12
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Aljumaah, M. R., Roach, J. M., Hu, Y., Gunstad, J., & Azcárate-Peril, M. A. (2025) · Science Advances · doi:10.1126/sciadv.ads5721 · Cited by 13
“Furthermore, in animal model studies, sitagliptin increased the relative abundance of Bacteroidetes , whereas saxagliptin decreased it ( 129 , 131 ).”
The new views on the state of the gut microbiota in obesity and diabetes mellitus type 2
Pokrovskaya, E. V., Шамхалова, М. Ш., & Shestakova, M. V. (2019) · Diabetes Mellitus · doi:10.14341/dm10194 · Cited by 15
Virwani, P. D., Cai, L., Yeung, P. K. K., Qian, G., Chen, Y., Zhou, L., Wong, J. W. H., Wang, Y., Ho, J. W. K., Lau, K. K., et al. (2022) · Microbiome · doi:10.1186/s40168-022-01366-0 · Cited by 10
“The Epac2–/– mice GM was characterized by significant alterations in several taxa which have been previously associated with metabolic diseases, including Mucispirillum [62], Oscillibacter [63], Marvinbryantia [64], Helicobacter [65], RC9 gut group [66], Thalassospira [67] and Epsilonbacteria [68].”
Backgroundde Macedo, J. C. C., Guadagnini, D., Assalin, H. B., Oliveira, E. S., Magro, D. O., Alborghetti, M. R., Sforça, M. L., Rocco, S. A., Santos, A., & Saad, M. J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12990-9 · Cited by 8
The Gut Gambit: A Review of How Microbial Imbalance Fuels Metabolic Mayhem
Venkata, L. N. S., Mishra, A. K., Mohanta, Y. K., Rustagi, S., Bahuguna, A., Tomar, A., Baek, K.-H., & Mishra, B. (2026) · Nutrients · doi:10.3390/nu18060888 · Cited by 9
“A multitude of formulations are successful against respiratory conditions, including asthma [227] and gut disorders such as IBS [228].”
The Gut–Brain Axis in Obesity: Mechanisms, Development, and Therapeutic Perspectives
Arellano-García, L., Portillo, M. P., Hadjihambi, A., Martinez, J. A., & Milton‐Laskibar, I. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00732-w · Cited by 8
“…pre - clinical studies described that its administration modulates gut microbiota composition towards a lean-related profile (enriched in bacteria from the genera Lactobacillus , Blautia and Turicibacter ) in diabetic mice with obesity and spon - taneous type 2 diabetic rats [ 81 , 82].”
Enhancing bile tolerance of Lactobacilli is involved in the hypolipidemic effects of liraglutide
Wang, C., Hu, H., Dong, Q., Huang, R., Zhao, W., Song, Y., Li, Z., Wang, N., Zhang, T., & Luo, X. (2021) · Bioscience Biotechnology and Biochemistry · doi:10.1093/bbb/zbab053 · Cited by 7
Liang, T., Jiang, T., Liang, Z., Li, L., Chen, Y., Chen, T., Yang, L., Zhang, N., Dong, B., Xie, X., et al. (2025) · Microbiological Research · doi:10.1016/j.micres.2025.128145 · Cited by 8
Metabolic consequences of alterations in gut microbiota induced by antidiabetic medications
Chaithanya, V., Kumar, J. S., Leela, K. V., Angelin, M., Satheesan, A., & Murugesan, R. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100180 · Cited by 6
Oral insulin does not alter gut microbiota composition of NOD mice
Kihl, P., Krych, Ł., Buschard, K., Wesley, J. D., Kot, W., Hansen, A. K., Nielsen, D. S., & von Herrath, M. G. (2018) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3010 · Cited by 6
Guraka, A., Sreedharan, S., Arasaradnam, R. P., Tripathi, G., & Kermanizadeh, A. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae172 · Cited by 5
Mechanistic Links Between the Gut Microbiome and Longevity Therapeutics
Garzon-Escamilla, N., Medina-Cardena, M., Roy, P., Trent, J., Jamous, J., Somesan, Y., & Denslow, S. (2026) · Biomedicines · doi:10.3390/biomedicines14020316 · Cited by 7
“Furthermore, in a mouse model of metabolic disease, liraglutide decreases genera previously associated with obesity, such as Roseburia , Marvinbryantia and Parabacteroides , and enriches lean-associated genera like Blautia and Coprococcus [187].”
SCFA producing bacteria shape the subtype of ADHD in childrenPreprint
Fan, C., Li, S., Wang, R., Fan, X., Liang, A., & Qi, K. (2019) · doi:10.21203/rs.2.16337/v1 · Cited by 6
Dinkov, B. (2026) · Biomedicines · doi:10.3390/biomedicines14061235 · Cited by 4
“In some, broader changes in microbiome composition were observed with-https out specific reporting of this taxon [63,65,70,72], underscoring the need for standardized methodological approaches in microbiome data analysis.”
Motte, L. R. D. L., Carreras, F., & Drago, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1858420 · Cited by 4
“…phylotypes associated with obesity (e.g., Roseburia, Erysipelotrichaceae Incertae Sedis, Marvinbryantia, Parabacteroides ) and enriched genera related to thinness (e.g. Blautia, Coprococcus ), while these changes were absent with saxagliptin, consistent with its neutral effect on body weight (29).”
Emerging therapeutic landscape: Incretin agonists in chronic kidney disease management
Lian, K., Zhang, K., Kan, C., Hou, N., Han, F., Sun, X., Qiu, H., & Guo, Z. (2024) · Life Sciences · doi:10.1016/j.lfs.2024.122801 · Cited by 6
Yulianto, W. A., Wulandari, W., & Pujimulyani, D. (2023) · Food Research · doi:10.26656/fr.2017.7(2).845 · Cited by 4
Mrozińska, S., Gosiewski, T., Sroka-Oleksiak, A., Szopa, M., Bulanda, M., Malecki, M. T., & Klupa, T. (2020) · Clinical Diabetology · doi:10.5603/dk.2019.0024 · Cited by 3
“observed an increase in the relative abundance of Firmicutes after administration of saxagliptin for 8 weeks [16], in contrast to the studies of Yan et al.”
ResultAbnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
Demidova, T. Y., Геннадьевна, Л. К., Korotkova, T. N., & Харчилава, Л. Д. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-1-24-42 · Cited by 3
“[76] Мыши с нормогликемией и гипергликемией, n=57 Mice with normoglycemia and hyperglycemia, n = 57 n=9 — нормогликемия, контроль/ normoglycemia, control n=10 — нормогликемия + саксаглиптин / normoglycemia + saxagliptin n=10 — нормогликемия + лираглутид /normoglycemia + liraglutide n=9 — гипергликеми, контроль / hyper…”
Gut microbiome alterations predict diabetic kidney disease in general populationPreprint
Zhao, Z., Zhang, W., Guo, R., Cui, W., Zhang, F., Geng, Y., Liu, C., Shang, J., Xiao, J., & Wen, X. (2020) · Research Square · doi:10.21203/rs.3.rs-104521/v1 · Cited by 3
“Diagnostic model consisting of genera Escherichia-Shigella and Prevotella_9 can distinguish 14 DNs from 14 DMs with 92% accuracy[9].”
Desmond, L. W., & Lowry, C. A. (2026) · Brain Behavior and Immunity Integrative · doi:10.1016/j.bbii.2026.100166 · Cited by 2
Liraglutide alters gut microbiota and improves endothelium-dependent relaxation in db/db mice
Oh, E. Y., Suh, S. H., Byeon, S., Lee, J., Lee, Y.-H., & Choi, S.-K. (2026) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2026.119042 · Cited by 3
Drug-Based Strategies for Weight Reduction and Their Interaction with the Human Gut Microbiota
Lee, V., Kim, E., & Singh, J. (2025) · Annals of Pharmacy Practice and Pharmacotherapy · doi:10.51847/oobvhfczjv · Cited by 2
Interaction between the gut microbiota and oral antihyperglycemic drugs
Buyvalenko, U. V., & Pokrovskaya, E. V. (2022) · Problems of Endocrinology · doi:10.14341/probl12835 · Cited by 2
Does Gut Microbiome Composition Influence the Efficacy of Psychiatric Drugs?
Suryawinata, N., & Mazmanian, S. K. (2025) · European Medical Journal · doi:10.33590/emj/cseb2440 · Cited by 2
Husník, R., Fletcher, J. M., Pilla, R., Ingram, D. K., Gaschen, F. P., Roth, G., Chen, C.-C., & Suchodolski, J. S. (2025) · Microbiology Research · doi:10.3390/microbiolres16080190 · Cited by 1
Olivares, D. V. F., Halverson, T., & Alagiakrishnan, K. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6020030 · Cited by 2
“For instance, Wang et al. 2016, demonstrated that liraglutide produced changes in gut microbiota in mice compared to the corresponding control [39].”
Effects of GLP ‐1 agonists on the gut microbiota in type 2 diabetes mellitus: a systematic review
Dantas, R. S., Santos, L. V. S., de Oliveira, A. G. C., Barreto, M. D. S., Silva, D. M. R. R., Moura, P. H. M., Silva, E. E. D., Santos, R. S., Santana, L. A. D. M., Gopalsamy, R. G., et al. (2026) · FEBS Journal · doi:10.1111/febs.70656 · Cited by 2
“In the end, 17 studies were included: 12 preclinical studies [27 – 38] and five clinical studies [18,39,40 – 42].”
Diabetes Mellitus and Microbiota: Knowledge and Perspectives
Rizzo, G. E., Rizzi, A., Tartaglione, L., Leo, M. L., Viti, L., Leo, M. A. S. D., & Pitocco, D. (2023) · Healthy ageing and longevity · doi:10.1007/978-3-031-14023-5_7 · Cited by 1
The role of the gut microbiota in the regulation of incretin effects
Shyshkan-Shyshova, К. О., & Zinych, O. V. (2020) · Clinical endocrinology and endocrine surgery · doi:10.30978/cees-2020-1-64 · Cited by 1
Medication and Health Risks Associated With Neglected Side Effects on Gut Microbiota
Velikova, T. V., Nakov, R., & Ianiro, G. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-819265-8.00074-7 · Cited by 1
Pharmacological methods for weight reduction and their connection with the human gut microbiota
Denchev, V. D., & Handjieva‐Darlenska, T. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e114567 · Cited by 1
“Wang et al. (2016) conducted an experiment in a mice model using subcutaneous injections of the GLP-1 receptor agonist liraglutide to determine whether the medication associated reduction of body weight is associated with alterations in gut microbiota.”
MethodA pro-, pre- és szinbiotikumok hatása a szénhidrát-, illetve lipidanyagcserére
Tomasics, G., Schandl, L., Polyák, A., & Winkler, G. (2024) · Orvosi Hetilap · doi:10.1556/650.2024.33064 · Cited by 1
Escalada, J. (2020) · Revista Española de Enfermedades Digestivas · doi:10.17235/reed.2020.7148/2020
Implications of microbiota in the pathogenesis of diabetes mellitus and cardiovascular disease
Tănase, D. M., Leustean, A. M., & Gosav, E. M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821039-0.00005-8
Lin, H. C., & Lin, D. M. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.727174792.793561058
Prijić, R., & Čuković‐Čavka, S. (2018) · Clinical gastroenterology · doi:10.1007/978-3-319-75856-5_9
If drugs with metabolic action affect the intestinal microbiota. Literature review
Fadieienko, G. D., Gridnyev, O., & Gridneiva, S. V. (2022) · Modern Gastroenterology · doi:10.30978/mg-2022-1-37
Medicinal-microbial interactions and ways of correcting iatrogenic intestinal dysbiosis
Бакулин, И. Г., & Serkova, M. Y. (2023) · Экспериментальная и клиническая гастроэнтерология · doi:10.31146/1682-8658-ecg-207-11-26-35 · Cited by 1
Demidova, T. Y., & Teplova, A. S. (2024) · Voprosy Pitaniya · doi:10.33029/0042-8833-2024-93-1-33-43
Gut Microbiota in Type 2 Diabetes
Ganguly, A., & Patra, F. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815324549125010008
Dinu, L.-D., Vamanu, E., & Avram, I. (2025) · Interdisciplinary biotechnological advances · doi:10.1007/978-981-95-2104-3_7
ALVARES, D. C. L. (2023) · TSpace (University of Toronto) · Cited by 1
The gut microbiome and metabolic health in aging
Sharma, S., & Gautam, G. J. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00003-1
Zouiouich, S. (2021) · theses.fr (ABES) · doi:10.70675/dccac4fez891dz478eza9f4zd925044d3025 · Cited by 1
Low Weight Loss Response to Incretin Analogs: A Systematic Review
Gaskin, P. S., & Chami, P. (2026) · Obesity Reviews · doi:10.1111/obr.70145
The Role of Microbiota in Type 1 Diabetes: Insights into Dysbiosis and Immune Interactions
Ignat, A., Anton, E., Săsăran, M. O., Tarnita, I., Ioniuc, I. K., Rusu, T. E., Moisă, Ș. M., Țarcă, E., Butnariu, L. I., Mitrofan, E. C., et al. (2026) · Nutrients · doi:10.3390/nu18121904
“Previous research has indicated that several medications commonly used in the treat-ment of T2D, such as metformin, liraglutide, and saxagliptin, may alter the composition of the gut microbiome [169,170].”
Al-Domi, H., Khalil, R., Batarseh, N., & aldomi, H. (2022) · Progress in nutrition · doi:10.23751/pn.v24i1.11502
Metadata
- Authors
- Wang, L., Li, P., Tang, Z., Yan, X., & Feng, B.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Feng, Bo
- Venue
- Scientific Reports
- Published
- 2016-09-16
- Volume
- 6
- Issue
- 1
- Pages
- 33251-33251
- ISSN
- 2045-2322 (ISSN-L)
- PMC
- PMC5025740
- OpenAlex
- W2519618698
- Cited by
- 165
- References
- 37
- Citations by year
- 2026: 14 · 2025: 16 · 2024: 16 · 2023: 19 · 2022: 19 · 2021: 19 · 2020: 20 · 2019: 22 · 2018: 12 · 2017: 6 · 2016: 2
- FWCI
- 7.27
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Scientific Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Chinese Medical Association (2011CB504006, 12030510351, PWZz2013-04)
- National Key Research and Development Program of China (2011CB504006, PWZz2013-04, 12030510351)
- Fundamental Research Funds for the Central Universities (1507219042)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- gut microbiota, liraglutide, saxagliptin, GLP-1 receptor agonists, body weight, weight loss, microbiota composition, dietary intake, blood glucose, 16S rRNA gene sequencing, ridge regression
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Gastrointestinal Microbiome, Liraglutide, Glucagon-Like Peptide-1 Receptor Agonists, Adamantane, Animals, Blood Glucose, Body Weight, Diabetes Mellitus, Experimental, Dipeptides, DNA, Bacterial, Eating, Feces, Hyperglycemia, Hypoglycemic Agents, Male, Mice, Inbred C57BL, RNA, Ribosomal, 16S, Streptozocin, Gene Expression, Mice, Knockout, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.